The biomanufacturing building boom is merging with several industry trends to create a looming overcapacity situation.
May 1, 2008
By:
Jim Miller
|
The current overcapacity situation in the bio/pharmaceutical industry is a reminder that CMOs need to come up with business models and value propositions that are based on more than just selling capacity.
Mar 1, 2008
By:
Jim Miller
|
The supply base for preclinical and clinical development services continues to expand in China.
Exubera and Cimzia provide a warning to CMOs that clinical and commercial success aren't guaranteed
Jan 1, 2008
By:
Jim Miller
|
A CMO faces significant risk of lost revenues and profits if the product fails in clinical trials or doesn't meet sales projections.
In the next 20 years, new outsourcing business models will enable biopharmaceutical companies to become more virtual.
Oct 1, 2007
By:
Jim Miller
|
There wasn't much of a contract services industry when BioPharm International began publishing 20 years ago. Today's big names in biomanufacturing, including Lonza, Boehringer-Ingelheim, and Avecia, had not yet entered the business.
Many service providers admit that their systems and management are inadequate to handle current growth—and more demand is coming in 2008
Sep 1, 2007
By:
Jim Miller
|
Meeting service levels is a major challenge for pharmaceutical services providers because the requirements of their client base vary widely.
European contract manufacturing organizations place sales representatives in US to tap into the growing market for biopharmaceutical development services
Jul 1, 2007
By:
Jim Miller
|
The BIO annual meeting in early May had an upbeat tone. Investment capital is flowing into the industry at high levels, resulting in strong demand for contract development services. The funding stream is particularly strong in the US, and that is attracting more European contract manufacturers (CMOs) eager to improve business development here.
Venture capital support for biopharma is strong, helping to boost CRO utilization to its limits
May 1, 2007
By:
Jim Miller
|
Venture capital insiders say that the flow of funds into biopharma shouldcontinue, driven by the large amount of money available for investment.
Small-scale biomanufacturers attract capital, while large CMOs build competitive barriers
Mar 1, 2007
By:
Jim Miller
|
The three largest players have accumulated, or are in the process of accumulating, nearly a million liters of capacity between them.
Lonza uses creative deal making and other people's money to climb to top position
Jan 1, 2007
By:
Jim Miller
|
The number of projects in Lonza's internal biomanufacturing pipeline grew by 40% to over 75 projects.
